

# ACCOMPLISHMENTS

	2005	2019
<b>Biobanking</b>	Limited	Repositories with hundreds of frozen tumor specimens
<b>Cell Lines</b>	Multiple invalid models	Misidentifications discovered; <b>valid cell line published!</b>
<b>Animal Models</b>	None	20+ mouse xenografts developed; first transgenic models
<b>Genomics</b>	Sporadic reports of translocations	<ul style="list-style-type: none"> <li>• Discovery of recurrent t(6;9) and MYB-NFIB fusion gene</li> <li>• Identification of additional molecular targets with potential therapies: NOTCH, FGFR, IGF-1R, HDAC</li> </ul>
<b>Preclinical Drug Screens</b>	None in valid models	<ul style="list-style-type: none"> <li>• Open xenograft platform for academia and industry</li> <li>• Strong relationships with biopharmaceutical companies</li> <li>• 100 anti-cancer compounds screened in xenografts</li> </ul>
<b>Mobilizing Patients</b>	Limited	Tissue donations, clinical trial accrual and \$15 million in donations
<b>NIH Commitments</b>	Negligible	Over \$25MM for salivary gland tumor research (NIDCR)
<b>Clinical Trials</b>	Few, small & haphazard	Multiple science-driven trials with improved designs, enrollment, data quality and patient outcomes

